

## Lifeclean Q3'2024 - A step back

Redeye saw sales development that was back to lower levels again. Sales development compared to last year's quarter was up 37%, however down significantly sequentially. We have scaled back sales to reflect the uncertainty regarding sales progression. There are many positive signals from the orders and agreements signed so far that have not paid off in steady sales. We have lowered our Base case to SEK 7.0 (8.0) per share and our Fair value range to SEK 3.0 - 13.6 (3.9 - 16.2) per share.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

## Attachments

Lifeclean Q3'2024 - A step back